+34 679 490 537info@nanbiosis.com

Posts on Jan 1970

Safe-N-Medtech kicks off in Bilbao

The Safe-N-MedTech European Project kcks off in Bibao to create an open innovation platform that accelerates the development of medical devices based on nanotechnologies.

During 2 and 3 of May took place in Bilbao, at the University of the Basque Country, the kick off meeting of the European project Safe-N-Medtech organized by Osteba, the HTA Unit of the Ministry of Health of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY.

Safe-N-Medtech, counts with 28 partnerts coordinated by TECNAN (Navarran company with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY, the research branch of the global health companies Keralty and Praxis. The new project is part of the Open Innovation Test Bed initiative (OITB) launched by the European Commission with the aim of accelerating the development of medical devices based on nanotechnologies in Europe and abroad. The project has a European funding of 15 million euros.

CIBER-BBN participates as a partner in the Safe-N-Medtech throught its Scientific Infraestructure, the ICTS NANBIOSISSeveral units of NANBIOSIS from CIBER-BBN and JUMISC wiil carry out some of the F/Q, in vivo and in vitro characterizations applied to pilot test cases, NANBIOSIS is the leader of WP3 Preclinical Research in nano-enabled MTs.

Society and clinical practice raise a growing demand for new biomaterials, ICTs, medical devices and in vitro diagnostics (Medical Technologies-MTs) based on micro and nanotechnologies. In addition to the challenge of time, new technologies are subject to other pressing factors, such as qualification, regulation, cost, biocompatibility and the need to be applicable throughout the world. Medical devices based on nanotechnologies can be applied in almost all medical areas, with an important presence in areas such as cancer, regenerative medicine, advanced therapies, neurology, cardiology, orthopedics and dentistry.

The initiative aims to build an open innovation platform to offer companies and reference laboratories the capabilities, knowledge, networks and services necessary for the development, testing, evaluation, improvement and exploitation of the market of medical devices and diagnostic based in nanotechnology. This platform will offer a multidisciplinary and market-oriented innovation approach for SMEs, health care providers and industries, accelerating the transfer to the market of these new medical devices. During the first years of project work, the partners will develop their services and test them in different case studies, so that, Safe-N-Medtech OITB can become a sustainable and competitive services platform for companies to accelerate their developments according to the necessary regulatory requirements and ensure the safety and effectiveness of their medical devices based on nanotechnologies.

Read More

Diabetes mellitus type 1: new system for treatment

The research carried out by the NanoBiocells group, coordinator of NANBIOSIS U10 Drug Formulation unit, from CIBER-BBN and UPV-EHU, with BIOMICS group of UPV-EHU was yesterday highlighted in Catalunya Vanguardista and Noticiasdelaciencia.com.

The research reduces the volume of implantation of microcapsules containing insulin-producing pancreatic cells by almost 80% thanks to an innovative system of Magnetic separation of microcapsules. In this way, the medical complications derived from the implantation of large volumes of microcapsules decrease and the treatment of type 1 diabetes mellitus improves.

More information:
https://www.catalunyavanguardista.com/nuevo-sistema-para-el-tratamiento-de-diabetes-mellitus-tipo-1/

Read More

Biomedical devices with natural fluorescence for monitoring in the body

Researchers from the NanoBioCel and the ICTS NANBIOSIS through the Drug Formulation Unit 10 of CIBER-BBN and the University of the Basque Country (UPV/EHU), together with the University of Michigan (USA), have developed a biomedical cellular immunoisolation device (microcapsules) with intrinsic capacity to be traced once implanted in the organism. The novel design incorporates a natural substance called genipine, which emits intense and stable fluorescence in the far red range. Drug Formulation Unit 10 of Nanbiosis has worked in the design and development of fluorescent particles for use in experimental animals.

Non-invasive monitoring of implanted hydrogel-based biosystems generally requires indirect vehicle or load marking, which increases complexity and the potential risk of altering their functionality. For the first time, this group of researchers has demonstrated that hydrogel-based biosystems can be produced from biomaterials with intrinsic properties for non-invasive monitoring, in this case through the use of genipine.

The work has recently been published in the Journal of Biophotonics and has been selected by the journal as a cover story in April.

It is important to note that to date no one has exploited the natural fluorescence emitted by genipine as a non-invasive monitoring system in cell therapies implanted in living beings,” the researchers point out. As a first milestone in this sense, we have developed a novel immunoisolation device that incorporates genipine into its own design, making it traceable once implanted in the body. Using a fast, efficient and non-cytotoxic procedure, we have managed to maximize the fluorescence of the microcapsules until an excellent signal-to-noise ratio is achieved. In addition, the group have validated the use of genipine as a quantitative imaging probe, demonstrating that intense and stable fluorescence is obtained with good signal linearity against doses of microcapsules implanted for several weeks. Through this strategy, they have been able to evaluate the actual injected dose immediately and control its position over time, which significantly improves the biosafety and efficacy of the therapy.

In addition, the idea may have a potentially successful application in the nano, micro and macro hydrogel-based technologies industry. These are called to be fundamental pieces both for biomedical research and for the advancement of clinical medicine through applications such as tissue engineering, regenerative medicine. “As fluorescence imaging systems are gradually implemented in clinical practice, we believe that our proposal could have a successful applicability in advancing multiple hydrogel-based biotechnologies, including drug and cell delivery systems, vaccines or biosensors,” they conclude.

Article of reference :

Edorta Santos‐Vizcaino, Henry Haley, Ainhoa Gonzalez‐Pujana, Gorka Orive, Rosa Maria Hernandez, Gary D. Luker, Jose Luis Pedraz. Monitoring implantable immunoisolation devices with intrinsic fluorescence of genipin. Journal of Biophotonics (April 2019) DOI: https://doi.org/10.1002/jbio.201800170

Read More

CIBER offers two Degree positions for NANBIOSIS (Project Mananger and Researcher) in the frame of a H2020 project.

CIBER-BBN offer two possitions for a project manager (PRF-1768 https://www.ciberisciii.es/empleo/detalle-oferta?id=1768 )  and a researcher (PRF-1766 https://www.ciberisciii.es/empleo/detalle-oferta?id=1766)

CIBER is looking for candidates for the selection of a project manager (https://www.ciberisciii.es/empleo/detalle-oferta?id=1768) and a researcher (ttps://www.ciberisciii.es/empleo/detalle-oferta?id=1766) to work in the framework of a European H2020 project.

SAFE-N-MEDTECH is an Open-Innovation Test Bed for Safety Testing of Medical Technologies for Health – H2020 NMBP (Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing) medtech project, that has just been launched.

The project SAFE-N-MEDTECH will build an innovative open access platform providing reference laboratories and companies with the capabilities, know-how, networks and services needed for developing, testing, evaluating, optimizing and marketing nanotechnology and diagnostic medical devices throughout the products’ entire lifecycle.

It is a project with duration of 4 years in which 28 partners participate including CIBER-BBN through NANBIOSIS (www.nanbiosis.es), a Research Infrastructure (RI) recognized as Unique Scientific-Technological Infrastructure (ICTS) by the Spanish Government for the Design, production and characterization of biomaterials, nanomaterials and devices up to preclinical validation.

In the framework of this project, CIBER-BBN offer two contracts in Valencia to work under the guidance of the Project leader:

Candidates must register from the CIBER website www.ciberisciii.es  in the employment section, searching the BBN area for calls 1444/1766 and 1445/1768 UNTILL MAY, 22, 2019

For further information you can contact: 

-Ramón Martínez Mañez (Project leader) rmaez@qim.upv.es

-Nerea Argárate (NANBIOSIS Coordinator) nargarate@ciber-bbn.es

Read More

The first Nanocomposite that slows the spread of colon cancer

The creation of a nanodrug capable of blocking the spread of the disease, which is known as metastasis, has been highlighted by Guia Medica, as a heavy blow struck against to colon cancer, the malignant tumor with the highest incidence in our country, a process that affects 40% of the million cases of this type of cancer that are diagnosed every year in the world, and that represents the main cause of death.

The research, jointly carried out by scientists from the IIB Sant Pau, Sant Pau Hospital, the UAB, CSIC and CIBER-BBN, led by Esther Vázquez and Antonio Villaverde, Strategy Director of NANBIOSIS U1. Protein Production Platform (PPP) in the IBB-UAB and Ramon Mangues, Scientific Director of NANBIOSIS U18. Nanotoxicology Unit in the Sant Pau Hospital, were published in the scientific journal EMBO Molecular Medicine ando pen a new way to prevent metastasis in colorectal cancer in humans, using a nanomedicine that selectively eliminates metastatic stem cells.

NANBIOSIS Unit 18 of Nanotoxicology has been involved in the study of the biodistribution and the antimetastatic effect and on normal organs of the nanoconjugate administered and the unit and Unit 1 PPP, has contributed to the production of the protein part of the nanoconjugate.

The new drug works like a drone that identifies a receptor (CXCR4) in metastatic stem cells. Once localized, it administers the drug and destroys it, blocking the metastasis, according to research sources. By acting only on metastatic tumor cells, the new nanodrug avoids the general toxicity associated with the usual treatments against cancer and preserves healthy cells. Although up to now it has been successfully tested in animals suffering from colorectal cancer, the researchers who have carried out the trial believe that it could be used in 20 types of additional tumors, which also express CXCR4, as in prostate, breast, ovarian and other tumors.

Read More

Polymers and medical applications: Success Cases of Preclinical Research

Next May 10, a conference on “Polymers and medical applications” will be held in Vizcaya, with the participation of NANBIOSIS Deputy Director, and JUMISC Scientific Director Dr. Francisco Miguel Sánchez Margallo, as guest speaker, who will give the lecture “Preclinical Research: Success Cases

The event will count also with the expertise of Dr. Miguel Angel Martínez, Scientific Director of NANBIOSIS U13 Tissue & Scaffold Characterization Unittalking about “Modeling and simulation in biomedical applications

Other topics that will be discussed at the Conference will be Hydrogels, Nanogels and Nanoparticles for Controlled Release of Bioactive Substances,
The Microfluidics as a Tool for the Development of “Organ-on-a-chip and the Use of Liquid Silicone in Devices for Cell Growth.

Leartiker is a team of researchers dedicated to R+D+I, specialized in Polymer Technology and belonging to the Basque Science and Technology Network (RVCTI).

Registration is free until full capacity is reached.

More information here.

Read More